Umavida Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Umavida Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $9.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Umavida Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $9.8M Trade | TransData Nexus

Umavida Pharma Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $9.8M Total Trade · DGFT Verified

Umavida Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $9.8M across 5 products in 3 therapeutic categories. Based on 197 verified export shipments from Indian Customs (DGFT) records, Umavida Pharma Private Limited is the #1 Indian exporter in 3 products including Bromhexine, Folic, Terbutaline. Top exports include Vitamin ($4.8M), Bromhexine ($2.6M), Folic ($1.1M).

Umavida Pharma Private Limited — Export Portfolio & Destination Treemap

Umavida Pharma Private Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Umavida Pharma Private Limited? — Company Overview & Market Position

Umavida Pharma Private Limited is a privately held pharmaceutical company incorporated on March 20, 2019, under the Corporate Identification Number (CIN) U24299GJ2019PTC107172. The company is registered with the Registrar of Companies, Ahmedabad, Gujarat, India. Its authorized share capital is ₹500,000, with a paid-up capital of ₹100,000.

Headquartered in Ahmedabad, Gujarat, Umavida Pharma operates a state-of-the-art manufacturing facility in Borisna, approximately 40 minutes from Ahmedabad. The facility spans 110,000 square feet of land, with a built-up area of 28,000 square feet, and is designed to adhere to international standards.

The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. As of March 2026, Umavida Pharma has achieved a total export value of $9.8 million USD, with 197 shipments covering five products across three therapeutic categories. The top five exported products are Vitamin, Bromhexine, Folic, Zinc, and Terbutaline, with Bromhexine leading the market with a 16.1% share.

What Does Umavida Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vitamin$4.8M

Product Portfolio — Top 5 by Export Value

Umavida Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vitamin	Nutritional Supplements	$4.8M	97	3.4%	2
2	Bromhexine	Respiratory & OTC	$2.6M	53	16.1%	1
3	Folic	Nutritional Supplements	$1.1M	23	2.0%	1
4	Zinc	Vitamins & Supplements	$800.0K	16	1.0%	6
5	Terbutaline	Respiratory & OTC	$400.0K	8	11.5%	1

Umavida Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $9.8M. The company is the #1 Indian exporter in 3 products: Bromhexine, Folic, Terbutaline. The top category is Nutritional Supplements (61.1% of portfolio), followed by Respiratory & OTC (30.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Umavida Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Umavida Pharma's manufacturing facility in Borisna, Gujarat, is equipped with advanced machinery to produce a range of pharmaceutical products. The facility includes fully automated units for liquid and oral syrups, tablets, capsules, and dry powders, ensuring minimal human intervention and adherence to international quality standards. The plant's production capacities are substantial, with daily outputs of 75,000 bottles for 10-15 ml syrups, 200,000 bottles for 60 ml syrups, 120,000 bottles for 100 ml syrups, 60,000 bottles for 200 ml syrups, 1,500,000 tablet units, 1,440,000 capsule units, and 60,000 dry powder bottles.

3Key Leadership

The leadership team at Umavida Pharma comprises several directors, including Varun Hasmukh Patel, Jagdishbhai Bhagwatbhai Desai, Shil Jitendra Shah, Fenil Jitendrakumar Shah, and Vipul Raghunath Chaudhari. Specific roles such as CEO, Managing Director, and CFO are not publicly disclosed. The company's registered office is located at Survey No.-396, Opp. Knack Packaging, Kadi-Thol Road, Village Borisana, Ta: Kadi, Dist: Mehsana 382715, Gujarat, India.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Umavida Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Umavida Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with international standards for pharmaceutical products. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed.

2Emerging Markets

Umavida Pharma has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company has pursued WHO prequalification to facilitate access to these regions, aligning its products with international quality standards to meet the needs of diverse patient populations. Specific details regarding WHO prequalification and market penetration strategies are not publicly disclosed.

3Geographic Strategy

Umavida Pharma's geographic strategy demonstrates a balanced approach, with a significant focus on both regulated and emerging markets. The company's export data indicates a diversified portfolio, mitigating concentration risk and positioning Umavida Pharma for sustained growth in various global markets. The strategic direction emphasizes expanding market presence while maintaining high-quality standards across all regions.

Umavida Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Umavida Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company is known to adhere to international quality standards, which may include compliance with FDA regulations for its products.

2WHO & EU GMP

Umavida Pharma is committed to maintaining high-quality standards, as evidenced by its state-of-the-art manufacturing facility designed to adhere to international standards. The company has pursued WHO prequalification to facilitate access to emerging markets, aligning its products with international quality standards. Specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

3CDSCO & Indian Regulatory

Umavida Pharma operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations and holds the necessary manufacturing licenses and approvals from state drug controllers. The company has obtained export No Objection Certificates (NOCs) to facilitate international trade. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export NOCs are not publicly disclosed.

Umavida Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Umavida Pharma operates in a competitive pharmaceutical market, with key competitors in overlapping categories such as Bromhexine, Folic, and Terbutaline. The company's market share in these categories indicates a strong position, with Bromhexine leading at 16.1%, Folic at 2.0%, and Terbutaline at 11.5%. A head-to-head analysis with competitors would require access to detailed market share data and competitor performance metrics, which are not publicly disclosed.

2Key Differentiators

Umavida Pharma's key differentiators include its state-of-the-art manufacturing facility adhering to international standards, a diversified product portfolio with a focus on high-demand therapeutic areas, and a commitment to quality assurance and regulatory compliance. The company's ability to maintain a 100% portfolio concentration in its top five products demonstrates a focused and effective product strategy.

3Strategic Position

Umavida Pharma's current strategic direction emphasizes the production of finished pharmaceutical formulations across various therapeutic areas, including cardiovascular, anti-diabetic, pain management, and respiratory systems. The company's future outlook involves expanding its market presence in both regulated and emerging markets, leveraging its manufacturing capabilities and commitment to quality to meet global healthcare needs.

Buyer Due Diligence Brief — Evaluating Umavida Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Umavida Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $9.8 million USD and 197 shipments across five products. The company's manufacturing facility is designed to adhere to international standards, ensuring product quality and reliability. While specific export volume consistency and reliability indicators are not publicly disclosed, the company's market share in key products suggests a reliable supply chain and customer satisfaction.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the FDA directly.

WHO-GMP Certification: Ensure that the manufacturing facility complies with World Health Organization Good Manufacturing Practice (WHO-GMP) standards. Verification can be done by reviewing the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Umavida Pharma Private Limited

How many pharmaceutical products does Umavida Pharma Private Limited export from India?

Umavida Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Vitamin ($4.8M), Bromhexine ($2.6M), Folic ($1.1M), Zinc ($800.0K), Terbutaline ($400.0K). Total export value is $9.8M.

What is Umavida Pharma Private Limited's total pharmaceutical export value?

Umavida Pharma Private Limited's total pharmaceutical export value is $9.8M, based on 197 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Umavida Pharma Private Limited the #1 Indian exporter?

Umavida Pharma Private Limited is the #1 Indian exporter in 3 products: Bromhexine (16.1% market share), Folic (2.0% market share), Terbutaline (11.5% market share).

What therapeutic categories does Umavida Pharma Private Limited cover?

Umavida Pharma Private Limited exports across 3 therapeutic categories. The largest are Nutritional Supplements (61.1%, 2 products), Respiratory & OTC (30.7%, 2 products), Vitamins & Supplements (8.1%, 1 products).

Get Full Umavida Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.